UCM924

UCM924 is a potent and selective small molecule partial agonist of the melatonin MT2 receptor. Developed primarily for the investigation of psychiatric and neurological conditions, it exhibits significantly higher affinity for the MT2 subtype compared to the MT1 receptor. Preclinical studies indicate that UCM924 modulates the sleep-wake cycle, circadian rhythms, and cortical inhibitory tone. In models of schizophrenia-like dysfunction, such as the MK-801 mouse model, UCM924 has demonstrated the ability to normalize hyperactivity and social interaction deficits. Its neurobiological effects are linked to the activation of c-Fos in parvalbumin-positive interneurons within the prefrontal cortex, thereby enhancing inhibitory neurotransmission. Unlike non-selective melatonin agonists, UCM924's subtype selectivity allows for the targeted modulation of specific symptom domains, such as positive-like and negative-like symptoms of schizophrenia, without broad sedative effects.

Other names

N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide